O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2000

Primary Completion Date

December 31, 2005

Conditions
Melanoma (Skin)
Interventions
DRUG

O6-benzylguanine

DRUG

carmustine

Trial Locations (13)

44708

Mercy Ireland Cancer Center, Canton

46617

Michiana Hematology/Oncology P.C., South Bend

60068

Lutheran General Cancer Care Center, Park Ridge

60153

Loyola University Medical Center, Maywood

60201

Evanston Northwestern Health Care, Evanston

60612

University of Illinois at Chicago Health Sciences Center, Chicago

60640

Louis A. Weiss Memorial Hospital, Chicago

61602

Oncology/Hematology Associates of Central Illinois, P.C., Peoria

62526

Decatur Memorial Hospital Cancer Care Institute, Decatur

62701

Central Illinois Hematology Oncology Center, Springfield

60637-1470

University of Chicago Cancer Research Center, Chicago

46885-5099

Fort Wayne Medical Oncology and Hematology, Incorporated, Fort Wayne

44106-5065

Ireland Cancer Center, Cleveland

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00005961 - O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma | Biotech Hunter | Biotech Hunter